Cellular immunotherapy for acute myeloid leukemia using dendritic cells pulsed with WT1 peptide and zoledronate
Phase 1
- Conditions
- acute myeloid leukemia
- Registration Number
- JPRN-UMIN000000796
- Lead Sponsor
- Department of Hematology and Oncology, Kyoto University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
1.There is deep seated active infection 2.There are other malignancies 3.There are leukemic lesions in the central nervous system 4.There is active autoimmune disease 5.Positive for HBs Ag, HCV Ab, HTLV-I Ab, HIV Ab, or serological test for syphilis 6.Responsible doctors judged the patient inappropriate for the trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method